Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Healthy volunteer Phase 1 single and multiple ascending dose clinical trial of ANB032

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled Healthy volunteer Phase 1 single and multiple ascending dose clinical trial of ANB032

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ANB 032 (Primary) ; ANB 032 (Primary)
  • Indications Inflammation
  • Focus Adverse reactions; First in man
  • Sponsors AnaptysBio

    • Most Recent Events

    • 11 Mar 2024 According to an AnaptysBio media release, results from this trial presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, CA, March 8-12, 2024.
    • 11 Oct 2023 According to an AnaptysBio media release, company announced upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023
    • 11 May 2023 According to an AnaptysBio media release, company announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top